‘Broad daylight dacoity’: SC on essential cancer drugs’ prices

1. At a Glance

• Supreme Court (Justices Vikram Nath and Sandeep Mehta) termed overpricing of essential cancer medicines a "broad daylight dacoity" against patients [1].
• Flags a systemic regulatory gap: India's drug price control regime (DPCO, 2013) leaves ~82% of medicines ("non-scheduled" drugs) without upfront price-fixation controls [3].
• High-value UPSC topic linking health governance, pharma regulation, judicial activism, and consumer rights — tests GS-II (governance) and GS-III (health/economy) simultaneously.

2. Why in the News

• On 23 September 2026, hearing two petitions (by Kishan Chand Jain and Dr Sanjay Kulshresthra) on drug price regulation, generics, medical devices and prescription practices, the SC flagged that a cancer drug had an MRP of ₹27,000 despite being supplied to retailers for ₹2,700 — a 10x markup [1][3].
• The Bench asked: "If this is not extortion, then what is it?" and criticised regulatory authorities for silence [1].

3. Background & Evolution

• Drugs (Prices Control) Order (DPCO), 2013, issued under the Essential Commodities Act, 1955, empowers the National Pharmaceutical Pricing Authority (NPPA) to fix ceiling prices for "scheduled" drugs listed in Schedule I [2].
• National List of Essential Medicines (NLEM), 2022 includes 63 anti-cancer drugs (including immunosuppressives and palliative-care medicines) [2].
• NPPA has separately used a Trade Margin Rationalisation (TMR) approach (capping trade margins at 30% for 42 select non-scheduled anti-cancer drugs), cutting MRPs of 526 brands by up to 90% [2].
• Example cited by NPPA: Erlotinib 150mg (Birlotib) MRP cut from ₹9,999 to ₹891.79 (−91%); Pemetrexed 500mg injection (Pemestar) cut from ₹25,400 to ₹2,509 (−90%) [2].
• Govt has also exempted Trastuzumab, Osimertinib, and Durvalumab from customs duty and cut GST to reduce MRPs [2].

4. Core Static Facts

5. Multi-Dimensional Analysis

Legal/Constitutional

• SC's oral observation invokes Article 21 (right to health as part of right to life) indirectly, by framing unaffordable essential medicine pricing as patient exploitation [1].
• Highlights a regulatory lacuna: DPCO 2013 controls only post-launch price hikes (>10%/year) for non-scheduled drugs, not the initial price fixation — a gap enabling arbitrary launch pricing [3].

Economic

• Non-scheduled drugs (82% of market) escape ceiling-price regulation, allowing manufacturers to build in high margins for retailers/private hospitals [3].
• TMR-style interventions have shown MRP cuts of up to 90% when trade margins are capped, indicating margin (not manufacturing cost) drives inflated prices [2].

Social

• Cancer treatment affordability directly affects catastrophic health expenditure and out-of-pocket spending, a key issue given India's low health insurance penetration.
• Disproportionately affects poorer patients without insurance, worsening health equity.

Governance/Administrative

• SC bench specifically criticised regulatory silence/inaction by authorities (implicitly NPPA/Health Ministry) despite the disparity being self-evident [1].
• Raises federal/administrative question of NPPA's regulatory mandate limits — e.g., Bombay HC has separately held NPPA cannot fix prices for non-scheduled formulations under current DPCO framework, exposing a jurisdictional gap.

6. Recent Developments (last 12–18 months)

• 23 September 2026: SC calls cancer drug overpricing "broad daylight dacoity," questions authorities' silence [1].
• NPPA's Trade Margin Rationalisation approach applied to 42 non-scheduled anti-cancer drugs, cutting MRPs of 526 brands up to 90% [2].
• Customs duty exemption and GST rate cuts announced for Trastuzumab, Osimertinib, and Durvalumab to reduce cancer drug MRPs [2].

7. Prelims Hooks

• DPCO stands for Drugs (Prices Control) Order, 2013, issued under the Essential Commodities Act, 1955.
• NPPA = National Pharmaceutical Pricing Authority — fixes ceiling prices for Schedule I ("scheduled") drugs.
• Roughly 82% of medicines in India are "non-scheduled" and escape upfront price-fixation control.
• Non-scheduled drug MRP cannot be hiked by more than 10% in a preceding 12-month period under DPCO 2013.
• NLEM 2022 contains 63 anti-cancer drugs.
• SC Bench in the case: Justices Vikram Nath and Sandeep Mehta.
• Cancer drug cited: MRP ₹27,000 vs. retailer supply price ₹2,700 (10x markup).
• NPPA's Trade Margin Rationalisation (TMR) approach caps trade margins on select non-scheduled anti-cancer drugs.
• Example price cuts under TMR: Erlotinib 150mg from ₹9,999 → ₹891.79; Pemetrexed 500mg injection from ₹25,400 → ₹2,509.
• Customs duty exemption/GST cuts applied to Trastuzumab, Osimertinib, Durvalumab.

8. Why the ₹27,000 Is Not Mostly the Company's Profit

• The big jump happens after the drug leaves the factory
• The price at which a company sells to the stockist is called Price to Stockist (PTS). The price printed on the box is the MRP.
• The gap between these two is the trade margin — money shared by stockists, chemists and hospitals.

• NPPA's own order recorded trade margins going as high as 1,800% or more on some cancer medicines [5].

• The regulator cannot see the gap it is supposed to control

• The Standing Committee on Chemicals and Fertilisers (report presented 1 December 2025) said PTS data "remains undisclosed to the public" [4].
• It asked the government to study the gap between PTS and retail price [4].

• So today nobody outside the company knows where the ₹24,300 difference in this case actually goes. That is why the Court is asking and the regulator has no clean answer [1].

• Why this matters for your answer — writing "companies overcharge" is too loose. The named fault is that the distribution chain, not manufacturing cost, carries the markup, and the data needed to prove it is not collected.

9. The Tool That Works Already Exists — but Only as a Temporary Order

• Trade Margin Rationalisation (TMR) is an emergency-type power, not a permanent rule
• Under DPCO 2013, NPPA can cap trade margins only "for a limited time period" — it is a special public-interest order, not a standing rule [4].

• So each time, NPPA must issue a fresh order for a fresh list of drugs. Drugs not on that list stay untouched.

• Where it has been used, it worked

• The 30% margin cap on 42 non-scheduled anti-cancer medicines cut MRPs of 526 brands by about 50% on average and saved patients roughly ₹984 crore a year [2].

• So the problem is not that the tool fails. It is that the tool is switched on drug-by-drug, and only sometimes.

• Department of Pharmaceuticals should amend DPCO 2013 to make TMR permanent

• This is not a wish — it is the Standing Committee's own recommendation, made in December 2025 [4].

• The same Committee also asked that NPPA's oversight be extended to non-scheduled formulations, which today have no price ceiling at all [4].

• Why an amendment, and not another court order — an oral remark by the Bench binds nobody. Changing the text of DPCO 2013 is what gives NPPA the standing power it currently lacks [1][4].

10. Where Companies Simply Step Outside the Rulebook

• Fixed dose combinations (FDCs) escape price control completely
• An FDC is two or more medicines mixed into one tablet or injection.
• The Standing Committee found that FDC drugs "escape NPPA price regulations entirely" [4].

• So a company can take a price-controlled molecule, combine it with another, and sell the combination at a free price. The ceiling on the single drug then means very little.

• Even capped products have crept back up

• Cardiac stents were brought under price control in 2017. Between 2017 and 2024, prices of bare metal stents still rose 44% and drug-eluting stents 29% [4].

• This is the honest lesson: a one-time cap is not a permanent fix. Without yearly review, prices climb back.

• The takeaway for Mains — India's price control is a list-based system. Anything outside the list — non-scheduled drugs, FDCs, new brands — is free-priced. The leak is built into the design, not caused by poor staffing [3][4].

11. The Strongest Argument Against Price Caps — and What It Gets Right

• The argument against
• If the government fixes low prices, companies may stop making the low-margin medicine, or not launch a new one in India at all. Patients then face a shortage, which is worse than a high price.
• Chemists and small stockists in villages survive on trade margin. Cut it too hard and the medicine may simply not be stocked far from cities.

• Price control also does not touch the other half of a cancer bill — hospital stay, tests, radiation.

• What is right in it — this is a real trade-off, and a good answer should concede it. Cheap medicine that is unavailable helps nobody.

• Where the argument fails in this case
• The 10x gap here is in the trade margin, not in the manufacturing cost [1][3]. Capping the margin at 30% still left the seller a margin — and still cut MRPs by about half [2].

• That is the key distinction to write: capping the trade margin is not the same as capping the manufacturer's price. The first squeezes the distribution chain; only the second can threaten supply.

• The wider point on affordability

• Out-of-pocket expenditure (OOPE — money a family pays from its own pocket at the time of treatment) fell from 62.6% of total health spending in 2014-15 to 39.4% in 2021-22, mainly because government health spending rose from 29% to 48% of the total [6].
• So price control is one lever, public spending is another. An answer that offers only price caps is incomplete.

12. Anchors for Answers

• Data: Cancer drug supplied to retailer at ₹2,700, MRP ₹27,000 — a 10x markup [1][3]
• Data: NPPA recorded trade margins on some cancer medicines of up to 1,800% [5]
• Data: 30% trade margin cap on 42 non-scheduled anti-cancer drugs cut MRPs of 526 brands by ~50% on average; ~₹984 crore saved yearly [2]
• Data: OOPE fell from 62.6% (2014-15) to 39.4% (2021-22) of total health expenditure; government share rose 29% → 48% [6]
• Data: Stent prices rose 44% (bare metal) and 29% (drug-eluting) between 2017 and 2024, despite being under price control [4]
• Report/Committee: Standing Committee on Chemicals and Fertilisers, report presented 1 December 2025 — recommended permanent trade margin rationalisation in DPCO 2013, NPPA oversight of non-scheduled formulations, and a study of the PTS-to-MRP gap [4]
• Law/Case: DPCO 2013 under the Essential Commodities Act, 1955; Article 21 (right to health as part of right to life); SC oral observation of 23 September 2026, Justices Vikram Nath and Sandeep Mehta [1]
• Scheme: Ayushman Bharat–PMJAY and Jan Aushadhi — the spending-side and generic-supply levers that sit alongside price control

13. Mains Relevance

• GS-II: Governance — Government policies and interventions for development in health sector; issues relating to development and management of Social Sector/Services.
• GS-III: Indian Economy — issues relating to planning, mobilization of resources; effects of liberalization on the economy; Health infrastructure.
• Sample stems: 1. Critically examine the regulatory gaps in India's Drug Price Control Order (DPCO), 2013, that allow arbitrary pricing of non-scheduled essential medicines. Suggest reforms. 2. Discuss the role of the National Pharmaceutical Pricing Authority in ensuring affordable access to essential medicines. What are its limitations? 3. Access to affordable healthcare is intrinsic to the Right to Life under Article 21. Discuss with reference to recent judicial observations on drug pricing.

14. Related Topics to Study Next

• National List of Essential Medicines (NLEM) — defines which drugs get price protection.
• Essential Commodities Act, 1955 — parent legislation enabling DPCO.
• Ayushman Bharat–PMJAY — link to catastrophic health expenditure and insurance coverage.
• Compulsory licensing & TRIPS flexibilities — related mechanism for affordable drug access (patented cancer drugs).
• Right to Health as part of Article 21 — constitutional basis for SC's health-related interventions.
• Generic drugs & Jan Aushadhi Yojana — parallel government affordability initiative.
• Bombay HC ruling on NPPA's jurisdiction over non-scheduled drugs — related legal precedent creating regulatory ambiguity.

15. Common Errors / Trap Areas

• Don't confuse "scheduled" vs "non-scheduled" drugs — only Schedule I (~1,000 drugs) has NPPA-fixed ceiling prices; non-scheduled drugs (82% of market) have only a cap on annual price increase, not initial price.
• Don't attribute DPCO to the Drugs and Cosmetics Act, 1940 — DPCO derives authority from the Essential Commodities Act, 1955.
• NPPA is not a constitutional or statutory body created by an Act of Parliament — it's an executive body (attached office of Dept. of Pharmaceuticals) created via government resolution.
• Trade Margin Rationalisation is an NPPA administrative measure, distinct from formal DPCO price-fixation — don't conflate the two mechanisms.
• This SC matter is at the hearing/observation stage (oral remarks), not a final judgment — avoid citing it as a binding "SC ruling on drug pricing."